Greg Deener

Company: iCell Gene Therapeutics

Job title: Chief Executive Officer

Seminars:

Panel Discussion: Making Cell Therapy for Autoimmune Diseases a Commercial Reality 3:45 pm

What challenges do we expect to encounter on our way towards commercial approval (i.e., regulatory, manufacturing, pricing)? With autoimmune diseases having larger patient population than oncology indications, how will we deal with the demand? How do we overcome these challenges to ensure we get better cell therapies for patients in need, faster?Read more

day: Conference Day Two

Developing Cutting Edge Life-Saving CAR-T Therapies for Systemic Lupus Erythematosus (SLE) Patients 9:50 am

Developing a compound chimeric antigen receptor (cCAR) targeting both CD19 and BCMA to exert more comprehensive killing and prevent antigen escape Sharing clinical data and long-term outcomes, with the first patient being administered over 4 years ago Demonstrating well tolerated, long-term remission in a single administrationRead more

day: Conference Day Two